Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin

Purpose: Inhibitors of endothelial cell proliferation, such as endostatin, result in suppression of tumor-associated angiogenesis and can achieve growth-inhibitory effects depending on the type of tumor treated. The purpose of this study was to investigate whether local overexpression of endostatin could serve to diminish tumor growth of bladder cancer in vivo. Experimental Design: We examined the capability of lentiviral-mediated gene transfer in vitro and therapeutic effects of lentivirus-based vectors expressing endostatin on tumor growth using an orthotopic human bladder tumor model. Results: We found that self-inactivating lentivirus vectors containing green fluorescent protein, alone or in combination with endostatin, were capable of efficient and stable gene transfer to a variety of human bladder tumor cell lines. The production and secretion of endostatin from lentivirus-transduced KU-7 human bladder cancer cells was confirmed by Western blot and competitive enzyme immunoassay. Intravesical instillation of untransduced, green fluorescent protein control lentivirus-transduced, and endostatin-transduced KU-7 cells was performed in murine models to establish orthotopic tumors. Sustained long-term expression of endostatin was achieved in lentivirus-transduced orthotopic bladder tumors, and it was associated with decreased vascularization and inhibition of tumor growth. Lentivirus vector-mediated overexpression of endostatin did not affect the intrinsic production of basic fibroblast growth factor and vascular endothelial growth factor. Conclusions: These findings suggest that lentivirus-mediated gene transfer might represent an effective strategy for expression of angioinhibitory peptides to achieve inhibition of human bladder cancer proliferation and tumor progression.

[1]  B. Teicher Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[2]  R. Audisio,et al.  Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion , 2004, Clinical & Experimental Metastasis.

[3]  R. Wagner,et al.  Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. , 2002, Cancer research.

[4]  Y. Gho,et al.  Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.

[5]  E. Chavakis,et al.  Dephosphorylation of endothelial nitric oxide synthase contributes to the anti‐angiogenic effects of endostatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  R. Timpl,et al.  Endostatin regulates endothelial cell adhesion and cytoskeletal organization. , 2002, Cancer research.

[7]  B. Bochner,et al.  Development of lentiviral vectors for antiangiogenic gene delivery , 2001, Cancer Gene Therapy.

[8]  G. Adessi,et al.  Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. , 2001, The Journal of urology.

[9]  A. Nienhuis,et al.  Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model , 2001, Cancer Gene Therapy.

[10]  D. Mukhopadhyay,et al.  Cell surface glypicans are low-affinity endostatin receptors. , 2001, Molecular cell.

[11]  T. Veikkola,et al.  Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Ahn,et al.  Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  I. Verma,et al.  Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[15]  R. Vile,et al.  A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy , 2000, Gene Therapy.

[16]  D. Kohn,et al.  Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. , 1999, Blood.

[17]  R. Bicknell,et al.  Antiangiogenic gene therapy , 1999, Gene Therapy.

[18]  D. Kohn,et al.  Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.

[19]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[20]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[21]  A. Harris,et al.  Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. , 1999, The Journal of urology.

[22]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[23]  V. Sukhatme,et al.  Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. , 1999, Cancer research.

[24]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[25]  H. Grossman,et al.  Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. , 1998, The Journal of urology.

[26]  U. Stenram Re: Gene therapy strategies for tumor antiangiogenesis. , 1998, Journal of the National Cancer Institute.

[27]  S. Campbell,et al.  Molecular mediators of angiogenesis in bladder cancer. , 1998, Cancer research.

[28]  R. Kumar,et al.  Angiogenic molecules and cancer metastasis. , 1998, In vivo.

[29]  R. Crystal,et al.  Gene therapy strategies for tumor antiangiogenesis. , 1998, Journal of the National Cancer Institute.

[30]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[31]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[32]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[33]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[34]  A. Harris,et al.  Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. , 1997, Cancer research.

[35]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[36]  D. Hanahan,et al.  Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. , 1996, European journal of cancer.

[37]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Folkman,et al.  Fighting cancer by attacking its blood supply. , 1996, Scientific American.

[39]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[40]  P. Carroll,et al.  Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. , 1995, The Journal of urology.

[41]  H. Shimada,et al.  Host organ specifically determines cancer progression. , 1995, Cancer research.

[42]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[43]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[44]  I. Pastan,et al.  Inhibition of VSV binding and infectivity by phosphatidylserine: Is phosphatidylserine a VSV-binding site? , 1983, Cell.